• Explore /
  • Poster
  • / A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.

A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.

Abstract Poster

Authors

Christine Chung

Christine H. Chung

Moffitt Cancer Center, Tampa, FL

Christine H. Chung , A. Dimitrios Colevas , Douglas Adkins , Michael K. Gibson , Cristina P. Rodriguez , Ammar Sukari , Julie E. Bauman , Lori J. Wirth , Faye M. Johnson , Nabil F. Saba , Barbara Burtness , Lara Dunn , Tanguy Y. Seiwert , Francis P. Worden , Jameel Muzaffar , Steven Margossian , Raymond Moniz , Steven N Quayle , Matteo Levisetti , Sara I. Pai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03978689

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 6045)

DOI

10.1200/JCO.2022.40.16_suppl.6045

Abstract #

6045

Poster Bd #

37

Abstract Disclosures

Similar Posters

First Author: Christine H. Chung

First Author: Michelle R. Abelson

First Author: David Rosen

First Author: Ulka N. Vaishampayan